Literature DB >> 22485010

Design of the novel protraction mechanism of insulin degludec, an ultra-long-acting basal insulin.

Ib Jonassen1, Svend Havelund, Thomas Hoeg-Jensen, Dorte Bjerre Steensgaard, Per-Olof Wahlund, Ulla Ribel.   

Abstract

PURPOSE: Basal insulins with improved kinetic properties can potentially be produced using acylation by fatty acids that enable soluble, high-molecular weight complexes to form post-injection. A series of insulins, acylated at B29 with fatty acids via glutamic acid spacers, were examined to deduce the structural requirements.
METHODS: Self-association, molecular masses and hexameric conformations of the insulins were studied using size exclusion chromatography monitored by UV or multi-angle light scattering and dynamic light scattering, and circular dichroism spectroscopy (CDS) in environments (changing phenol and zinc concentration) simulating a pharmaceutical formulation and changes following subcutaneous injection.
RESULTS: With depletion of phenol, insulin degludec and another fatty diacid-insulin analogue formed high molecular mass filament-like complexes, which disintegrated with depletion of zinc. CDS showed these analogues adopting stable T(3)R(3) conformation in presence of phenol and zinc, changing to T(6) with depletion of phenol. These findings suggest insulin degludec is dihexameric in pharmaceutical formulation becoming multihexameric after injection. The analogues showed weak dimeric association, indicating rapid release of monomers following hexamer disassembly.
CONCLUSIONS: Insulins can be engineered that remain soluble but become highly self-associated after injection, slowly releasing monomers; this is critically dependent on the acylation moiety. One such analogue, insulin degludec, has therapeutic potential.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22485010      PMCID: PMC3399081          DOI: 10.1007/s11095-012-0739-z

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  28 in total

1.  Structural effects of protein lipidation as revealed by LysB29-myristoyl, des(B30) insulin.

Authors:  H B Olsen; N C Kaarsholm
Journal:  Biochemistry       Date:  2000-10-03       Impact factor: 3.162

2.  Ultra-long-acting insulin degludec has a flat and stable glucose-lowering effect in type 2 diabetes.

Authors:  T Heise; L Nosek; S G Bøttcher; H Hastrup; H Haahr
Journal:  Diabetes Obes Metab       Date:  2012-07-10       Impact factor: 6.577

3.  Biochemical and physiological properties of a novel series of long-acting insulin analogs obtained by acylation with cholic acid derivatives.

Authors:  Ib Jonassen; Svend Havelund; Ulla Ribel; Anne Plum; Mette Loftager; Thomas Hoeg-Jensen; Aage Volund; Jan Markussen
Journal:  Pharm Res       Date:  2006-12-21       Impact factor: 4.200

Review 4.  How to achieve a predictable basal insulin?

Authors:  P Kurtzhals
Journal:  Diabetes Metab       Date:  2005-09       Impact factor: 6.041

5.  The mechanism of protraction of insulin detemir, a long-acting, acylated analog of human insulin.

Authors:  Svend Havelund; Anne Plum; Ulla Ribel; Ib Jonassen; Aage Vølund; Jan Markussen; Peter Kurtzhals
Journal:  Pharm Res       Date:  2004-08       Impact factor: 4.200

6.  Albumin-bound basal insulin analogues (insulin detemir and NN344): comparable time-action profiles but less variability than insulin glargine in type 2 diabetes.

Authors:  O Klein; J Lynge; L Endahl; B Damholt; L Nosek; T Heise
Journal:  Diabetes Obes Metab       Date:  2007-05       Impact factor: 6.577

7.  Albumin binding of insulins acylated with fatty acids: characterization of the ligand-protein interaction and correlation between binding affinity and timing of the insulin effect in vivo.

Authors:  P Kurtzhals; S Havelund; I Jonassen; B Kiehr; U D Larsen; U Ribel; J Markussen
Journal:  Biochem J       Date:  1995-12-15       Impact factor: 3.857

8.  Lower within-subject variability of insulin detemir in comparison to NPH insulin and insulin glargine in people with type 1 diabetes.

Authors:  Tim Heise; Leszek Nosek; Birgitte Biilmann Rønn; Lars Endahl; Lutz Heinemann; Christoph Kapitza; Eberhard Draeger
Journal:  Diabetes       Date:  2004-06       Impact factor: 9.461

9.  Insulin degludec in type 1 diabetes: a randomized controlled trial of a new-generation ultra-long-acting insulin compared with insulin glargine.

Authors:  Kåre I Birkeland; Philip D Home; Ulrich Wendisch; Robert E Ratner; Thue Johansen; Lars A Endahl; Karsten Lyby; Johan H Jendle; Anthony P Roberts; J Hans DeVries; Luigi F Meneghini
Journal:  Diabetes Care       Date:  2011-01-26       Impact factor: 19.112

10.  Strategies for the assessment of protein aggregates in pharmaceutical biotech product development.

Authors:  John den Engelsman; Patrick Garidel; Ronald Smulders; Hans Koll; Bryan Smith; Stefan Bassarab; Andreas Seidl; Otmar Hainzl; Wim Jiskoot
Journal:  Pharm Res       Date:  2010-10-23       Impact factor: 4.200

View more
  139 in total

Review 1.  Oxidation of therapeutic proteins and peptides: structural and biological consequences.

Authors:  Riccardo Torosantucci; Christian Schöneich; Wim Jiskoot
Journal:  Pharm Res       Date:  2013-09-25       Impact factor: 4.200

Review 2.  Insulin therapy in children and adolescents with type 1 diabetes.

Authors:  Faisal S Malik; Craig E Taplin
Journal:  Paediatr Drugs       Date:  2014-04       Impact factor: 3.022

3.  A novel insulin combination of insulin degludec and insulin aspart achieves a more stable overnight glucose profile than insulin glargine: results from continuous glucose monitoring in a proof-of-concept trial.

Authors:  Andreas Liebl; Jaime Davidson; Henriette Mersebach; Patrik Dykiel; Cees J Tack; Tim Heise
Journal:  J Diabetes Sci Technol       Date:  2013-09-01

4.  Authors' Reply to Gough: "Achieving Glycaemic Control with Concentrated Insulin in Patients with Type 2 Diabetes".

Authors:  Sudesna Chatterjee; Kamlesh Khunti; Melanie Davies
Journal:  Drugs       Date:  2019-04       Impact factor: 9.546

5.  Basal insulin reductions in anticipation of multiple exercise sessions in people with type 1 diabetes-a clinical perspective.

Authors:  Olivia McCarthy; Steve C Bain; Rachel Deere
Journal:  Ann Transl Med       Date:  2018-12

6.  Structure-based stabilization of insulin as a therapeutic protein assembly via enhanced aromatic-aromatic interactions.

Authors:  Nischay K Rege; Nalinda P Wickramasinghe; Alisar N Tustan; Nelson F B Phillips; Vivien C Yee; Faramarz Ismail-Beigi; Michael A Weiss
Journal:  J Biol Chem       Date:  2018-06-07       Impact factor: 5.157

7.  Chemical Strategies for Half-Life Extension of Biopharmaceuticals: Lipidation and Its Alternatives.

Authors:  Esben M Bech; Søren L Pedersen; Knud J Jensen
Journal:  ACS Med Chem Lett       Date:  2018-06-15       Impact factor: 4.345

Review 8.  Insulin analogues in type 1 diabetes mellitus: getting better all the time.

Authors:  Chantal Mathieu; Pieter Gillard; Katrien Benhalima
Journal:  Nat Rev Endocrinol       Date:  2017-04-21       Impact factor: 43.330

9.  Insulin therapies: Current and future trends at dawn.

Authors:  Subhashini Yaturu
Journal:  World J Diabetes       Date:  2013-02-15

Review 10.  Controlled release of biologics for the treatment of type 2 diabetes.

Authors:  Caslin A Gilroy; Kelli M Luginbuhl; Ashutosh Chilkoti
Journal:  J Control Release       Date:  2015-12-02       Impact factor: 9.776

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.